Clinicopathological features of NTRK3 gene rearrangement papillary thyroid carcinoma.
10.3760/cma.j.cn112151-20210826-00606
- VernacularTitle:NTRK3重排甲状腺乳头状癌的临床病理学特征
- Author:
Hou Qiang LI
1
;
Xiao Yan CHEN
2
;
Xun Bin YU
2
;
Lin Ying CHEN
3
;
Xia ZHANG
2
;
Long JIN
2
;
Yi Juan WU
2
;
Zhi Zong CHEN
2
Author Information
1. Department of Pathology, Fujian Provincial Hospital South Branch, Fuzhou 350028, China.
2. Department of Pathology, Fujian Provincial Hospital, Fuzhou 350001, China.
3. Department of Pathology, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
- Publication Type:Journal Article
- MeSH:
Biomarkers, Tumor;
Female;
Gene Rearrangement;
Humans;
In Situ Hybridization, Fluorescence;
Mutation;
Proto-Oncogene Proteins B-raf/genetics*;
Receptor, trkC;
Retrospective Studies;
Thyroid Cancer, Papillary/genetics*;
Thyroid Neoplasms/genetics*
- From:
Chinese Journal of Pathology
2022;51(2):126-131
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the clinicopathological features and differential diagnosis of NTRK3 gene rearrangement thyroid papillary carcinoma (PTC). Methods: The PTC cases without BRAF V600E mutation were collected at Fujian Provincial Hospital South Branch from January 2015 to January 2020. The cases of NTRK3 gene rearrangement PTC were examined using immunohistochemistry and fluorescence in situ hybridization (FISH). The clinical data, histopathological characteristics, immunohistochemical features and molecular pathological changes were retrospectively analyzed. Data from the TCGA PTC dataset and the literature were also studied. Results: A total of 3 PTC cases harboring NTRK3 gene rearrangement were confirmed. All the patients were female, aged from 26,49,34 years. Histologically, two of them demonstrated a multinodular growth pattern. Only one case showed prominent follicular growth pattern; the other two tumors showed a mixture of follicular, papillary and solid growth patterns. All tumors showed a typical PTC nuclear manifestation, with some nuclear pleomorphism, vacuolated foci and oncocytic features. The characteristic formation of glomeruloid follicular foci was present in two cases which also showed psammoma bodies, and tumoral capsular or angiolymphatic invasion. The background thyroid parenchyma showed chronic lymphocytic thyroiditis. Mitotic rates were low, and no cases had any tumor necrosis. The pan-TRK and TTF1 testing was both positive in 3 cases, while S-100 and mammaglobin were both negative in them. FISH studies confirmed the NTRK3 gene rearrangement in all 3 cases. Studies on the TCGA datasets and literature revealed similar findings. Conclusions: NTRK3 gene rearrangement PTC is rare. It may be easily misdiagnosed due to the lack of histological and clinicopathological characteristics. Molecular studies such as pan-TRK immunostaining, FISH and even next-generation sequencing are needed to confirm the diagnosis. Immunohistochemistry of pan-TRK performed in the PTC cases without BRAF V600E mutation can be used as a good rapid-screening tool. With the emergence of pan-cancer tyrosine receptor kinase inhibitors, proper diagnosis of these tumors can help determine appropriate treatments and improve their outcomes.
